Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06821503 | Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C | recruiting | Phase 1 / Phase 2 | 72 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06646055 | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 110 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors(MAST) | terminated | Phase 1 | 66 | Imugene LimitedINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05846867 | A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 170 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05078866 | Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients | active not recruiting | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | Mar 3, 2026 | clinicaltrials |
| NCT06938321 | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 135 | AkesoINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03828799 | Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer(FOLFIRINOX-R) | completed | Phase 1 / Phase 2 | 13 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04526106 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 490 | Elevar TherapeuticsINDUSTRY | 13 | Feb 27, 2026 | clinicaltrials |
| NCT07049055 | A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer(Carolyn-USA) | recruiting | Phase 1 / Phase 2 | 144 | Engeneic Pty LimitedINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435584 | Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)(EVER-RECODE) | not yet recruiting | Phase 1 / Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07441174 | IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 92 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04761185 | Raltitrexed in HIPEC | completed | Phase 1 | 30 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05642962 | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | active not recruiting | Phase 1 / Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | completed | Phase 1 / Phase 2 | 51 | Lokon Pharma ABINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | terminated | Phase 1 | 17 | Accent TherapeuticsINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07425483 | CAR-NK Cells (CL-NK-003) in Pancreatic Cancer | recruiting | Phase 1 | 9 | Changhai HospitalOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05488522 | SBRT With Atezo/Bev for HCC | recruiting | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 21 | PfizerINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT07281716 | Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC | recruiting | Phase 1 / Phase 2 | 24 | Dan FengOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT02021422 | A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy | completed | Phase 1 | 13 | Baylor Research InstituteOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05096715 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | recruiting | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06217094 | Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT02073994 | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | completed | Phase 1 | 174 | Institut de Recherches Internationales ServierOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT04418401 | Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients(CISLD-8) | completed | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | withdrawn | Phase 1 / Phase 2 | 0 | Institut de Recherches Internationales ServierOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT07145255 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | MBrace TherapeuticsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07411781 | PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases | not yet recruiting | Phase 1 | 25 | Chinese PLA General HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03065062 | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors | suspended | Phase 1 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03785873 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 34 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
| NCT06384560 | Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)(PREOPANC-5) | recruiting | Phase 1 / Phase 2 | 66 | Amsterdam UMC, location VUmcOTHER | 1 | Feb 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2026source: clinicaltrials